Anne Macy

Mrs. Anne Macy

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
AAAnngela C. Adams
Anngela C. Adams
AMAnne Macy
Anne Macy
KSKathylynn Saboda
Kathylynn Saboda
SDSally Dickinson
Sally Dickinson
DGDavid J. Glembocki
David J. Glembocki
KHKaren Taraszka Hastings
Karen Taraszka Hastings

28 April 2022 in Cancers
Verified
Journal Article
Open access
PDF file
AAAnngela Adams
Anngela Adams
EBElizabeth Borden
Elizabeth Borden
AMAnne Macy
Anne Macy
NTNick Thomson
Nick Thomson
HCHaiyan Cui
Haiyan Cui
KHKaren Taraszka Hastings
Karen Taraszka Hastings
Gamma-interferon-inducible lysosomal thiol reductase (GILT) is critical for MHC class II restricted presentation of multiple melanoma antigens. There is variable GILT protein expression in malignant melanocytes in melanoma specimens. High GILT mRNA expression in melanoma specimens is associated with improved overall survival, before the advent of immune checkpoint inhibitors (ICI). However, the association of GILT in metastatic melanoma with survival in patients treated with ICI and the cell type expressing GILT associated with survival have not been determined. Using RNA sequencing datasets, high GILT mRNA expression in metastatic melanoma specimens was associated with improved progression-free and overall survival in patients treated with ICI. A clinical dataset of metastatic melanoma specimens was generated and annotated with clinical information. Positive GILT immunohistochemical staining in antigen presenting cells and melanoma cells was observed in 100% and 65% of metastatic melanoma specimens, respectively. In the subset of patients treated with ICI in the clinical dataset, high GILT protein expression within melanoma cells was associated with improved overall survival. The association of GILT mRNA and protein expression with survival was independent of cancer stage. These studies support that high GILT mRNA expression in bulk tumor samples and high GILT protein expression in melanoma cells is associated with improved survival in ICI-treated patients. These findings support further investigation of GILT as a biomarker to predict the response to ICI.

22 October 2025 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
AAAnngela C Adams
Anngela C Adams
AMAnne Macy
Anne Macy
EBElizabeth S Borden
Elizabeth S Borden
LHLauren M Herrmann
Lauren M Herrmann
CBChad A Brambley
Chad A Brambley
KHKaren Taraszka Hastings
Karen Taraszka Hastings
Background: Challenges in predicting which neoantigens mediate tumor rejection limit the efficacy of neoantigen vaccines to treat cancers, especially for cancers with a high mutational burden like cutaneous squamous cell carcinoma (cSCC). Only a small portion of neoantigens prioritized by current methods elicit effective T cell responses, demonstrating the critical need for improved criteria for the prediction of tumor-rejecting neoantigens. Methods: Publicly available human cSCC datasets were used to assess the frequency of shared mutations between patients. A transplantable ultraviolet light-induced mouse model of cSCC was generated. The mutational signature and driver mutations in the mouse model were compared with human tumors. Neoantigens were prioritized in the mouse model, and tumor-rejecting neoantigens were identified through (enzyme-linked immunosorbent spot (ELISpot) and in vivo prophylactic vaccination. Binding of the neoantigens and corresponding wild-type peptides to major histocompatibility complex (MHC) class I was determined. Structural modeling of peptide:MHC complexes was performed to assess for changes in structural characteristics of the neoantigens relative to the wild-type peptides. Results: A minority of human cSCC tumors shared neoantigens. The mouse cSCC model recapitulated the mutational signature and driver mutations found in human disease and was constrained by CD8 T cells. Two MHC class I neoantigens were identified in the mouse model that constrained cSCC growth. One tumor-rejecting neoantigen exhibited improved MHC binding, and the other had increased solvent accessibility of the mutated residue, compared with wild-type. Across known neoantigens that do not impact MHC binding, increased exposure of the mutated residue distinguished tumor-rejecting from non-immunogenic neoantigens. Conclusions: Given the paucity of shared mutations, this work supports the need for personalized neoantigen vaccines in cSCC. To facilitate further discovery, we provide a clinically relevant mouse cSCC model with two defined neoantigens that mediate tumor rejection. Structural changes in the exposure of features that promote T cell receptor recognition defined tumor-rejecting neoantigens. Incorporation of structural modeling to predict changes in T cell receptor accessibility is anticipated to improve the selection of neoantigens for inclusion in personalized cancer vaccines.

1 November 2021 in Translational Oncology
Verified
Journal Article
Open access
AAAnngela C Adams
Anngela C Adams
AMAnne Macy
Anne Macy
PKPaul Kang
Paul Kang
KCKarla F. Castro-Ochoa
Karla F. Castro-Ochoa
EWE.M. Kithsiri Wijeratne
E.M. Kithsiri Wijeratne
KHKaren Taraszka Hastings
Karen Taraszka Hastings
Melanoma is an aggressive skin cancer that metastasizes to other organs. While immune checkpoint blockade with anti-PD-1 has transformed the treatment of advanced melanoma, many melanoma patients fail to respond to anti-PD-1 therapy or develop acquired resistance. Thus, effective treatment of melanoma still represents an unmet clinical need. Our prior studies support the anti-cancer activity of the 1713-hydroxywithanolide class of natural products, including physachenolide C (PCC). As single agents, PCC and its semi-synthetic analog demonstrated direct cytotoxicity in a panel of murine melanoma cell lines, which share common driver mutations with human melanoma; the IC50 values ranged from 0.19-1.8 mu M. PCC treatment induced apoptosis of tumor cells both in vitro and in vivo. In vivo treatment with PCC alone caused the complete regression of established melanoma tumors in all mice, with a durable response in 33% of mice after discontinuation of treatment. T cell-mediated immunity did not contribute to the therapeutic efficacy of PCC or prevent tumor recurrence in YUMM2.1 melanoma model. In addition to apoptosis, PCC treatment induced G0-G1 cell cycle arrest of melanoma cells, which upon removal of PCC, re-entered the cell cycle. PCC-induced cycle cell arrest likely contributed to the in vivo tumor recurrence in a portion of mice after discontinuation of treatment. Thus, 1713-hydroxywithanolides have the potential to improve the therapeutic outcome for patients with advanced melanoma.

18 June 2026
Verified
Other
Open access
HCHaroldo J. Rodriguez Chevez
Haroldo J. Rodriguez Chevez
ARAllison J. Remington
Allison J. Remington
MGMatthew D. Gray
Matthew D. Gray
RARian Alam
Rian Alam
MGMacy W. Gilmour
Macy W. Gilmour
JTJustin J. Taylor
Justin J. Taylor
Tumor sample cohort patient history summaries.

18 June 2026
Verified
Other
Open access
HCHaroldo J. Rodriguez Chevez
Haroldo J. Rodriguez Chevez
ARAllison J. Remington
Allison J. Remington
MGMatthew D. Gray
Matthew D. Gray
RARian Alam
Rian Alam
MGMacy W. Gilmour
Macy W. Gilmour
JTJustin J. Taylor
Justin J. Taylor
Merkel cell carcinomas (MCC) typically arise from the clonal integration of the Merkel cell polyomavirus. Immunogenic viral oncoproteins then lead to tumorigenesis. Oncoprotein-specific T cells are essential for anti-MCC immunity, but it is unclear whether B cells promote tumor control. In this study, we analyzed the frequency and phenotype of viral oncoprotein–specific and total B cells in blood samples from 47 patients with MCC and tumor samples from another 19 patients with MCC. The phenotype of blood B cells did not correlate with the outcomes of patients with MCC. In contrast, all 11 patients with robust oncoprotein-specific antibody-secreting and/or germinal center B cells in tumors experienced long-term MCC control. In vitro, B cells engineered to be specific for viral oncoproteins increased the sensitivity of oncoprotein-specific CD4+ T cells by more than 50-fold. Together, our findings suggest that cancer-specific B cells promote antitumor immunity via increased responses by T cells and that cancer-specific augmentation of B cells could be therapeutically relevant.See related Spotlight, p. 716